Overview
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)
Status:
Recruiting
Recruiting
Trial end date:
2026-05-01
2026-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of cardiovascular events after acute myocardial infarction in patients with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Karolinska InstitutetCollaborators:
Capio Sankt Görans Hospital
The Swedish Research Council
Uppsala UniversityTreatments:
Metformin
Criteria
Inclusion Criteria:I. AMI
II. Swedish citizens with a personal ID number ≥18 years and ≤80 years
III. Newly diagnosed prediabetes:
1. HbA1c 42-47 mmol/mol or
2. Capillary or venous fasting plasma glucose concentration 6.1-6.9 mmol/L or
3. 2-hour post-load capillary glucose concentration 8.9-12.1 mmol/L or
4. 2-h post-load venous plasma glucose concentration 7.8-11.0 mmol/L
5. HbA1c <48 mmol/mol and 2-hour post-load capillary glucose concentration >12.1 mmol/L
or 2-h post-load venous plasma glucose concentration >11.0 mmol/L (thus elevated
2-hour glucose levels in the diabetes range but without HbA1c levels diagnostic for
diabetes)
IV. Naïve to metformin and other glucose lowering therapy
V. Signed informed consent
Exclusion Criteria:
I. Type 1 diabetes
II. Known type 2 diabetes
III. Indication for glucose lowering treatment
IV. Acute condition with high risk for volume depletion, circulatory shock, hypoxia
V. Serious illness, other than cardiovascular, with short life expectancy
VI. Renal failure (eGFR <60ml/min)
VII. Hepatic failure
VIII. Malignancy within the last year
IX. Contraindication or hypersensitivity to the study drug
X. Alcohol or drug abuse
XI. Pregnancy or breastfeeding
XII. Women of childbearing potential without adequate anticonception during any part of the
study period
XIII. Previous hospitalisation for lactic acidosis
XIV. Predicted inability to comply with the study protocol